Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PDE2A | O00408 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9987929 | 1.00 | KMT2A (0.44) | KMT2APDE2APOLBSMN1; SMN2TSHR | |
| SCHEMBL3074268 | 1.00 | KMT2A (0.44) | KMT2APDE2APOLBSMN1; SMN2TSHR | |
| SCHEMBL23122207 | 1.00 | KMT2A (0.44) | KMT2APDE2APOLBSMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL27204271 | 0.98 | KMT2A (0.43) | KMT2APDE2APOLBSMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL29106444 | 0.98 | KMT2A (0.43) | KMT2APDE2APOLBSMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL27160078 | 0.98 | KMT2A (0.43) | KMT2APDE2APOLBSMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL30615195 | 0.98 | KMT2A (0.43) | KMT2APDE2APOLBSMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL30049359 | 0.98 | KMT2A (0.43) | KMT2APDE2APOLBSMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL29106441 | 0.98 | KMT2A (0.43) | KMT2APDE2APOLBSMN1; SMN2TSHR | |
| SCHEMBL22158761 | 0.86 | KIF11 (0.44) | KDM4EHPGDALDH1A1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4330231-A1 | 2-METHYLENE-4-OXO-BUTANOIC ACID DRIVATIVES FOR THE TREATMENT OF INFLAMMATION | Sitryx Therapeutics Limited (GB) | 2024-03-06 | — | — | EP | disclosed |
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-4031552-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2022-07-27 | — | — | EP | disclosed |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| CN-114728975-A | Azole-fused pyridazin-3 (2H) -one derivatives | 武田药品工业株式会社 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021055326-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | WO | disclosed |
| US-20200347049-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2020-11-05 | — | — | US | disclosed |
| US-8008487-B2 | Substituted thieno[2,3-D]pyrimidines as fungicides | DOW AGROSCIENCES LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008487-B2 | Substituted thieno[2,3-D]pyrimidines as fungicides | DOW AGROSCIENCES LLC (US) | 2011-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347049-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | KMT2A 4819/4885PDE2A 1158/4885POLB 4582/4885 |
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | GPR139, GPR119, GPR39 | KMT2A 4524/4885PDE2A 414/4885POLB 4591/4885 |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | KMT2A 4819/4885PDE2A 1158/4885POLB 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.